Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests earlier treatment for low blood sugar in type 1 diabetes

NCT ID NCT04876079

Knowledge-focused Sponsor: Institut de Recherches Cliniques de Montreal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving oral glucose at a slightly higher blood sugar threshold can prevent mild-to-moderate hypoglycemia in people with type 1 diabetes. Thirty adults with type 1 diabetes were given 16g of oral carbohydrates when their blood glucose reached a target level. The goal was to see if this proactive approach reduces time spent with low blood sugar compared to current guidelines.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral glucose (16g carbohydrates)
What this could lead to
If successful, this could lead to simpler, more effective guidelines for preventing mild low blood sugar episodes in people with type 1 diabetes.
What could go wrong
This is a small, early study with only 30 participants. The results may not apply to everyone, and the approach might not work better than current guidelines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jun 2021

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and females ≥ 18 years old 2. Clinical diagnosis of type 1 diabetes for at least one year 3. Treatment with multiple daily insulin injections or insulin pump therapy with insulin analogs (rapid, ultra-rapid and basal insulin) 4. A glycated hemoglobin A1c ≤ 10% Exclusion Criteria: 1. Clinically significant microvascular complications: nephropathy (eGFR \< 40 ml/min), severe proliferative retinopathy as judged by the investigator, neuropathy (particularly diagnosed gastroparesis) 2. Recent (\< 3 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery) 3. Known significant cardiac rhythm abnormality based on investigator's judgement 4. Known significant neurological abnormality (e.g., seizure disorder) based on investigator's judgement 5. Ongoing pregnancy or breastfeeding 6. Severe hypoglycemia episode within 1 month of screening 7. Known uncorrected hypokalemia within the past 3 months (potassium \< 3.5 mmol/L)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypoglycemia type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • Montreal Clinical Research Institute

    Montreal, Quebec, H2W 1R7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.